Zora
Providing diagnostic solutions for improved health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
€300k | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 49 % | (71 %) | (27 %) | (22 %) | 104 % | (55 %) | 1214 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 108 % | (614 %) | (661 %) | (576 %) | (326 %) | (620 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (153 %) | (1495 %) | (1796 %) | (2074 %) | (1169 %) | (2252 %) | (122 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 935 % | 1064 % | 1304 % | - | - | - | - |
Source: Company filings or news article
Related Content
Zora Biosciences operates in the diagnostics sector, focusing on identifying markers of disease and developing them into robust, high throughput clinical methods. The company primarily serves healthcare providers and patients, offering innovative diagnostic solutions that enhance the accuracy and efficiency of disease detection and management. Zora's flagship product, the CERT Coronary Event Risk Test, is a blood-based diagnostic tool that identifies patients at risk of heart attack or cardiovascular death, even when other clinical parameters suggest otherwise. This test is particularly valuable for patients with stable coronary heart disease who are on optimal medical therapy. In Finland, the CERT test is marketed under the name Hertta.
Zora Biosciences generates revenue through the sale of its diagnostic tests and related services. The company operates in the global healthcare market, with a particular focus on cardiovascular health. By providing high-value diagnostic solutions, Zora aims to improve patient outcomes and reduce healthcare costs.
Keywords: diagnostics, disease markers, clinical methods, healthcare, cardiovascular, CERT test, coronary risk, blood-based test, high throughput, patient outcomes.